Increased protein SUMOylation following focal cerebral ischemia
Introduction
Cerebral ischemia has profound effects on multiple cellular processes including posttranslational modification of proteins (Dorval and Fraser, 2007, Durukan and Tatlisumak, 2007). One such posttranslational modification is SUMOylation that occurs when Small Ubiquitin like MOdifier (SUMO), a 97-residue protein, covalently binds to lysine residues on target proteins. Protein SUMOylation has been most extensively studied in the nucleus where it can alter the subcellular localization, protein partnering, and DNA-binding and/or transactivation functions of transcription factors (Hilgarth et al., 2004).
There are four SUMO paralogues (SUMO-1–4) in vertebrates. Of these SUMO-4 is mainly localized to the kidney (Bohren et al., 2004) while the other forms are present in brain. SUMO-2 and SUMO-3 differ by only four N-terminal amino acids and no difference in their functional roles has yet been reported (Hay, 2005). Together SUMO-2/3 shares only ∼50% sequence identity to SUMO-1.
It is becoming increasingly apparent that protein SUMOylation is involved in diverse cellular processes including transcriptional regulation, nuclear transport, maintenance of genome integrity, cell signalling, plasma membrane depolarization and signal transduction (Johnson, 2004, Wilson and Rosas-Acosta, 2005, Kerscher et al., 2006, Scheschonka et al., 2007). The functional consequences of SUMO attachment vary greatly from substrate to substrate, and in many cases are not well understood. SUMO-1 and SUMO-2/3 also differ in their conjugation dynamics and responses to cellular stress. Under resting conditions, very little SUMO-1 is present in an unconjugated form, yet there is a large free pool of SUMO-2/3. In response to cellular stresses, such as oxidative stress, osmotic stress or heat shock, an increase in SUMO-2/3 conjugation occurs suggesting that SUMO-2/3 could act as a cellular SUMO reserve to allow an efficient response to stress (Saitoh and Hinchey, 2000).
Protein SUMOylation is dramatically increased in the brain of ground squirrels during hibernation and it has been proposed that this may provide a mechanism to protect cells from otherwise lethally low levels of oxygen and glucose due to reduced blood flow (Lee et al., 2007). Furthermore, recently it has been reported that transient global cerebral ischemia induces a marked increase in protein SUMOylation in the hippocampus and cerebral cortex by SUMO-2/3 in mice (Yang et al., in press).
There are multiple SUMOylated proteins at synapses (Martin et al., 2007) consistent with bioinformatics analysis data indicating that a diverse range of synaptic proteins are potential SUMO targets (Yang et al., 2006). More specifically, the KAR subunit GluR6 is a SUMO target. GluR6 exhibits low levels of SUMOylation under resting conditions but is rapidly SUMOylated in response to agonist activation. Reducing GluR6 SUMOylation using the specific de-SUMOylation enzyme SENP-1 prevented the agonist-evoked KAR endocytosis. KAR-mediated excitatory postsynaptic currents (EPSCs) in hippocampal slices are decreased by SUMOylation and enhanced by de-SUMOylation (Martin et al., 2007). This is of interest because GluR6 has been implicated in neuronal cell death following ischemic insult via a JNK activation pathway (Pei et al., 2006, Zhang et al., 2006) and KARs are also involved in ischemia-induced white matter injury (Tekkok et al., 2007). Therefore, we formulated the hypothesis that one role of increased SUMOylation could be to down-regulate the surface expression of KARs, which in turn, would reduce excitotoxicity and subsequent cell death.
Here we have investigated changes in the pattern of protein SUMOylation and in levels of AMPAR and kainate receptor subunits in MCAO-induced focal ischemia in rat and mouse, which is a model for human stroke. In mice permanent middle cerebral artery occlusion results in a cortical infarct whereas in rat transient MCAO results in a predominantly striatal infarct. At 6 h and 24 h post-MCAO, ischemic tissue from cortex and striatum was dissected and processed to analyse protein SUMOylation. In addition, non-ischemic hippocampal tissue was analysed from both MCAO models. Thus we studied protein SUMOylation in brain tissue from the infarcted area as well as outside the ischemic regions from two different species with or without reperfusion. Our data show that ischemia evokes dramatic changes in the pattern of protein SUMOylation and causes decreases in both AMPAR and KAR levels.
Section snippets
Methods
Animal care and all experimental procedures were conducted in accordance with Danish animal protection legislation and the experimental protocols were approved by the Danish National Committee for Ethics in Animal Research.
Areas of MCAO-induced infarct in rat and mouse
Transient MCAO in Wistar rats results in a striatal and neocortical infarct (Fig. 1A) whereas permanent MCAO in NMRI mice produces a neocortical infarct as illustrated in Fig. 1B.
Effects of transient MCAO in rat on total levels of protein SUMOylation
First we tested if levels of SUMO-1 and SUMO-2/3 SUMOylated proteins were altered by transient MCAO induced by the intraluminal filament technique in rats that results in a unilateral predominantly striatal infarct. Ipsilateral and contralateral striata and hippocampi were collected from rats 6 h and 24 h after MCAO. In
Discussion
Our results demonstrate that two different models of ischemia in two different species lead to profound changes in the levels of protein SUMOylation by both SUMO-1 and SUMO-2/3 in infarct areas. As summarised in Table 1, following transient ischemia in rats SUMO-1 increased at 6 h and 24 h in the ischemic striatum with no detectable changes outside the infarct area either in contralateral striatum or hippocampus. SUMO-2/3, on the other hand, increased in the infarct area at 6 h and 24 h and in the
Acknowledgements
H.C. is a Marie Curie Travelling Research Fellow. This work was funded by the MRC, the Wellcome Trust and EU grants GRIPPANT (contract number 005320) and ENI-NET (contract number 019063). We thank Dr. M. Dasso (NIH, USA) for the gift of polyclonal anti-SUMO-1 and anti-SUMO-2/3 antibodies. We are also grateful to Dr. Stepháne Martin for advice and expert comments on the manuscript and Philip Rubin and Charlotte L. Petersen for technical assistance.
References (24)
- et al.
A M55V polymorphism in a novel SUMO gene (SUMO-4) differentially activates heat shock transcription factors and is associated with susceptibility to type I diabetes mellitus
J. Biol. Chem.
(2004) - et al.
The SUMO isopeptidase Ulp2 prevents accumulation of SUMO chains in yeast
J. Biol. Chem.
(2003) - et al.
SUMO on the road to neurodegeneration
Biochim. Biophys. Acta
(2007) - et al.
Acute ischemic stroke: overview of major experimental rodent models, pathophysiology, and therapy of focal cerebral ischemia
Pharmacol. Biochem. Behav.
(2007) SUMO: a history of modification
Mol. Cell
(2005)- et al.
Regulation and function of SUMO modification
J. Biol. Chem.
(2004) - et al.
Ca2+-permeable AMPA receptors in synaptic plasticity and neuronal death
Trends Neurosci.
(2007) - et al.
Functional heterogeneity of small ubiquitin-related protein modifiers SUMO-1 versus SUMO-2/3
J. Biol. Chem.
(2000) - et al.
Sumoylation in neurons: nuclear and synaptic roles?
Trends Neurosci.
(2007) - et al.
Polymeric chains of SUMO-2 and SUMO-3 are conjugated to protein substrates by SAE1/SAE2 and Ubc9
J. Biol. Chem.
(2001)
Antioxidant N-acetylcysteine inhibits the activation of JNK3 mediated by the GluR6-PSD95-MLK3 signaling module during cerebral ischemia in rat hippocampus
Neurosci. Lett.
Protein modification by SUMO
Annu. Rev. Biochem.
Cited by (90)
Trophic factor BDNF inhibits GABAergic signaling by facilitating dendritic enrichment of SUMO E3 ligase PIAS3 and altering gephyrin scaffold
2022, Journal of Biological ChemistryPost-treatment with apocynin at a lower dose regulates the UPR branch of eIF2α and XBP-1 pathways after stroke
2022, Brain Research BulletinPrasugrel anti-ischemic effect in rats: Modulation of hippocampal SUMO2/3-IкBα/Ubc9 and SIRT-1/miR-22 trajectories
2021, Toxicology and Applied PharmacologyCitation Excerpt :While bountiful stress response pathways are activated within ischemic brains, especially upon reperfusion, a great interest stands out with the SUMOylation process (Bernstock et al., 2018). The reports around this process is controversial; though SUMOylation is highly endorsed as an important neuroprotective machinery affecting transcription factors that modulate gene expression (Cimarosti et al., 2008; Lee et al., 2009), yet this process can also be a way to mark the SUMOylated substrate for degradation (Hochrainer, 2018). According to the type of SUMO protein, the substrate can be either kept stable or marked for proteosomal degradation.
Resilience to Injury: A New Approach to Neuroprotection?
2020, NeurotherapeuticsSUMOylation participates in induction of ischemic tolerance in mice
2019, Brain Research Bulletin